Sarepta Therapeutics, Inc. (SRPT) is listed on NASDAQ in Pharmaceutical Stocks. It is $20.85, -3.45%, with a $2.2B market cap. RSI is 65.2, near overbought. The latest reported quarter beat estimates. Insiders were net sellers across the listed trades.
Technical Analysis
RSI (14) 65.2 Near Overbought
Market Cap $2.2B
Volume 3.5M
Fundamentals — 10-Q Q2 2026
Revenue $1.1B
Net Income $326.1M
EPS $2.99
Operating Margin 32.8%
Net Margin 28.8%
Debt / Equity 0.6x
P/E Ratio 7.0x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Mayo Stephen | Insider | Sell | 7,239 | $17.02 | $123,208 | 2026 Mar 12 |
| Estepan Ian Michael | Chief Operating Officer | Sell | 13,187 | $22.31 | $294,202 | 2025 Dec 16 |
| Nicaise Claude | Director | Sell | 2,491 | $99.64 | $248,203 | 2025 Mar 12 |
| Wigzell Hans Lennart Rudolf | Director | Sell | 10,500 | $124.84 | $1.3M | 2024 Dec 12 |
| Boor Kathryn Jean | Director | Sell | 1,636 | $125.55 | $205,400 | 2024 Dec 5 |
| Estepan Ian Michael | Chief Financial Officer | Sell | 5,985 | $137.36 | $822,100 | 2024 Aug 30 |
| Chambers Michael Andrew | Director | Buy | 37,038 | $133.80 | $5.0M | 2024 Aug 16 |
| Brown Ryan Edward | EVP, General Counsel | Sell | 38,957 | $161.61 | $6.3M | 2024 Jun 25 |
| Arif Bilal | Chief Tech Ops Officer | Sell | 11,757 | $163.13 | $1.9M | 2024 Jun 25 |
| Murray Dallan | Chief Customer Officer | Sell | 3,635 | $140.00 | $508,900 | 2024 May 2 |
| Boor Kathryn Jean | Director | Sell | 761 | $122.93 | $93,550 | 2024 Mar 11 |
| Wigzell Hans Lennart Rudolf | Director | Sell | 15,000 | $123.25 | $1.8M | 2024 Mar 8 |
| Mayo Stephen | Director | Sell | 3,135 | $122.96 | $385,480 | 2024 Mar 5 |
| Brown Ryan Edward | EVP, General Counsel | Sell | 2,000 | $125.34 | $250,680 | 2024 Mar 1 |
| Estepan Ian Michael | Chief Financial Officer | Sell | 1,200 | $128.30 | $153,960 | 2024 Mar 1 |
| Arif Bilal | Chief Tech Ops Officer | Sell | 2,000 | $128.84 | $257,676 | 2024 Mar 1 |
| Ingram Douglas S | President & CEO | Buy | 25,225 | $79.36 | $2.0M | 2023 Nov 3 |
| Barry Richard | Director | Buy | 50,000 | $78.81 | $3.9M | 2023 Nov 3 |
| Chambers Michael Andrew | Director | Buy | 9,979 | $109.47 | $1.1M | 2023 Aug 14 |
| Chambers Michael Andrew | Director | Buy | 23,686 | $108.05 | $2.6M | 2023 Aug 11 |
Other Pharmaceutical Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $1,173.34 | 46.3 | $1.1T |
| | $268.01 | 58.6 | $645.9B |
| | $148.31 | 64.1 | $365.9B |
| | $13.17 | 50.0 | $2.7B |
| | $34.70 | 44.3 | $25.1B |
| | $36.44 | 58.3 | $42.5B |
| | $60.85 | 58.2 | $26.8B |
Take SRPT further
- Browse Pharmaceutical Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put SRPT in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Sarepta Therapeutics, Inc. next reports.
Set alerts on SRPT
Get notified when Sarepta Therapeutics, Inc. hits your price targets or technical conditions are met.
Get Started Free